Dermapharm Holding SE
DMPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,181 | $1,151 | $1,025 | $943 |
| % Growth | 2.6% | 12.3% | 8.7% | – |
| Cost of Goods Sold | $414 | $447 | $364 | $322 |
| Gross Profit | $767 | $704 | $661 | $621 |
| % Margin | 65% | 61.2% | 64.5% | 65.8% |
| R&D Expenses | $12 | $20 | $13 | $14 |
| G&A Expenses | $14 | $20 | $16 | $13 |
| SG&A Expenses | $88 | $95 | $67 | $66 |
| Sales & Mktg Exp. | $75 | $75 | $51 | $53 |
| Other Operating Expenses | $450 | $230 | $3 | $8 |
| Operating Expenses | $550 | $521 | $419 | $334 |
| Operating Income | $217 | $183 | $244 | $298 |
| % Margin | 18.4% | 15.9% | 23.8% | 31.7% |
| Other Income/Exp. Net | -$45 | -$77 | -$27 | -$5 |
| Pre-Tax Income | $172 | $106 | $216 | $293 |
| Tax Expense | $60 | $45 | $84 | $84 |
| Net Income | $114 | $62 | $134 | $210 |
| % Margin | 9.6% | 5.4% | 13.1% | 22.2% |
| EPS | 2.11 | 1.16 | 2.49 | 3.89 |
| % Growth | 81.9% | -53.4% | -36% | – |
| EPS Diluted | 2.11 | 1.16 | 2.49 | 3.89 |
| Weighted Avg Shares Out | 54 | 54 | 54 | 54 |
| Weighted Avg Shares Out Dil | 54 | 54 | 54 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $2 | $0 | $4 |
| Interest Expense | $58 | $55 | $15 | $9 |
| Depreciation & Amortization | $90 | $102 | $95 | $55 |
| EBITDA | $321 | $263 | $324 | $357 |
| % Margin | 27.2% | 22.8% | 31.6% | 37.9% |